Company / Cash & Equivalents
MADRIGAL PHARMACEUTICALS, INC. Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$198.7M
FY2025
5-year range
$36.3M / $331.5M
FY2021-FY2025
Trend
+98.7%
vs FY2024
Sector context
#86 of 207
Health Care
What the data says
At $199M, MADRIGAL PHARMACEUTICALS, INC.'s cash & equivalents ranks #86 of 207 in the Health Care sector. Cash & Equivalents has fluctuated over the past 10 years, ranging from $19M in FY2016 to $332M in FY2022.
Based on SEC 10-K filings.
$199M in FY2025 with a 5-year CAGR of +29.8%.
Improved from $100M to $199M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -15.7%
- 5-Year CAGR
- +29.8%
- 10-Year CAGR
- -
Sector benchmark
#86 of 207 in Health CareTop 42% of 207This company $198.7M Sector average $669.5M
▼
-70.3% below sector average
Key checks
Key Insights
- 5-year CAGR of +29.8%, indicating consistent growth.
- In FY2025, cash & equivalents increased 98.7% year-over-year.
- Ranks #86 out of 207 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2022.
Company context
Key Data Points
- Altman Z-Score -0.47 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $198.7M | +98.7% |
| FY2024 | $100.0M | +0.1% |
| FY2023 | $99.9M | -69.9% |
| FY2022 | $331.5M | +814.1% |
| FY2021 | $36.3M | -32.8% |
| FY2020 | $54.0M | +15.6% |
| FY2019 | $46.7M | -18.6% |
| FY2018 | $57.4M | -61.4% |
| FY2017 | $148.6M | +676.3% |
| FY2016 | $19.1M | +12830.0% |
As of FY2025 · SEC 10-K · Updated Mar 29, 2026